title: Increased iodine uptake in thyroid carcinoma after treatment with sodium butyrate and decitabine (5-Aza-dC).
abstract: OBJECTIVE
  To determine if epigenetic-modifying drugs can increase iodine uptake in thyroid carcinoma cell lines.
  
  
  METHODS
  Human thyroid carcinoma cell lines were tested for iodine uptake before and after treatment with epigenetic-modifying agents.
  
  
  RESULTS
  Thyroid carcinoma cell lines DRO and 2-7 had high levels of DNA methylation (74% and 80%) compared with normal thyroid tissue (6%) (P < 0.05). This finding correlated with low levels of sodium iodide symporter (NIS) expression in the untreated thyroid carcinoma cell line. Combination treatment with the epigenetic-modifying agents 5-aza-2'-deoxycytidine and sodium butyrate resulted in increases in NIS messenger RNA levels, global histone acetylation, and 9- and 8-fold increases in I(125) uptake for the DRO and 2-7 cells, respectively.
  
  
  CONCLUSIONS
  Epigenetic-modifier drugs represent a novel adjuvant treatment for those patients with radioablation-resistant thyroid cancer.
  
  
  CONCLUSIONS
  Epigenetic-modifying agents show potential for treatment of radioablation-resistant thyroid cancer.
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, University of Iowa, Iowa City, IA, USA.
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Provenzano
authors.forename: Matthew P
authors.initials: MP
authors.lastname: Fitzgerald
authors.forename: Kimberly
authors.initials: K
authors.lastname: Krager
authors.forename: Frederick E
authors.initials: FE
authors.lastname: Domann
mesh_terms: D000107:Acetylation / Q000187:drug effects; D001374:Azacitidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D015153:Blotting, Western; D002087:Butyrates / Q000008:administration & dosage*; D045744:Cell Line, Tumor; D019175:DNA Methylation / Q000187:drug effects; D000077209:Decitabine; D004359:Drug Therapy, Combination; D044127:Epigenesis, Genetic / Q000187:drug effects*; D006801:Humans; D007457:Iodine Radioisotopes / Q000378:metabolism* / Q000627:therapeutic use; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000032:analysis; D012974:Sodium Iodide / Q000378:metabolism; D027981:Symporters / Q000032:analysis / Q000235:genetics; D013964:Thyroid Neoplasms / Q000378:metabolism / Q000532:radiotherapy*
chemical_list: D002087:Butyrates; D007457:Iodine Radioisotopes; D012333:RNA, Messenger; D027981:Symporters; D000077209:Decitabine; D012974:Sodium Iodide; D001374:Azacitidine